HMI-115 not checked
Hope Medicine (Nanjing) Co., Ltd
FollowEvery change as it happens, and a Monday email
Trials
1 active
4 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Endometriosis
- Main trialPhase 3
- “A phase 3 study to evaluate the efficacy and safety of HMI-115 in women with moderate to severe endometriosis-associated pain over a 24-week treatment period and a 28-week extension”In the company’s words, NCT07318688 on ClinicalTrials.gov
Other drugs for Endometriosis
- ElagolixAbbVie · Phase 3
- LinzagolixKissei Pharmaceutical Co., Ltd. · Phase 3
- RelugolixSumitomo Pharma America, Inc. · Phase 3
- VipoglanstatGesynta Pharma AB · Phase 2
- Teverelix DPAntev Ltd. · Phase 2
- HHK001Huahai Pharmaceutical (Huaota) · Phase 1
Coming up1
- 1 Mar 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 1 Mar 2028 | Evaluate the Efficacy and Safety of HMI-115 in Women With Moderate to Severe Endometriosis-associated Pain | |
| Phase 2Completed | 26 Aug 2024 | A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia | |
| Phase 2Completed | 26 Sep 2024 | A Study to Assess the Efficacy and Safety of HMI-115 in Subjects With Endometriosis-Associated Pain | |
| Phase 1Completed | 11 Sep 2023 | To Evaluate the Safety, Tolerability and Efficacy in Male and Female with AGA Treated with HMI-115 Over a 24-week Treatment Period |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026